Fresenius Medical Care AG: Form 20-F for the period ended Dec 31, 2019
Filed with the SEC on Feb 20, 2020 and accepted by EDGAR at Feb 20, 2020, 13:52 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2019-01-01 to 2019-12-31 | EUR 17.48bn | ifrs-full:Revenue |
| Cost of revenue | 12 months2019-01-01 to 2019-12-31 | EUR 12.08bn | ifrs-full:CostOfSales |
| Gross profit | 12 months2019-01-01 to 2019-12-31 | EUR 5.40bn | ifrs-full:GrossProfit |
| Operating income | 12 months2019-01-01 to 2019-12-31 | EUR 2.27bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months2019-01-01 to 2019-12-31 | EUR 401.6m | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2019-01-01 to 2019-12-31 | EUR 1.20bn | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months2019-01-01 to 2019-12-31 | EUR 3.96 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2019-01-01 to 2019-12-31 | EUR 3.96 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | EUR 2.57bn | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | EUR 1.12bn | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2019-12-31 | EUR 1.01bn | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2019-12-31 | EUR 7.17bn | ifrs-full:CurrentAssets |
| Total assets | At period end2019-12-31 | EUR 32.93bn | ifrs-full:Assets |
| Current liabilities | At period end2019-12-31 | EUR 7.01bn | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2019-12-31 | EUR 19.71bn | ifrs-full:Liabilities |
| Shareholders' equity | At period end2019-12-31 | EUR 11.96bn | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | At period end2019-12-31 | 298,329,247 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001047469-20-000960. Last ingested by Listed: Nov 3, 2026, 10:24 ET. Listed shows no prices and gives no investment advice.